Tango Therapeutics, Inc. (TNGX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$22.53+1.35%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put TNGX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Control operating losses near or below -$49 million per quarter: Operating income: $-59.78M.
View ThesisRevenue growth is accelerating — up about 48% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 34% in its worst 12-month stretch.
View RiskTNGX’s vopimetostat trials are the central bet, but the latest earnings miss weakens the case. The company is advancing vopimetostat trials after positive Phase 1/2 data. Its latest quarter missed GAAP EPS consensus by 19.4%. Revenue growth is unclear because the desk gives no latest revenue figure. TNGX trades at 43× sales versus a 10× peer median. The market is pricing in more growth than our forecast, so that premium needs evidence. Our model puts the next-quarter miss probability near 45%. Operating income of -$59.78 million pressures the loss-control pillar. Peer multiples imply a price about 35% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. TNGX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 13 analysts currently covering TNGX (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for TNGX in the last 4 months.
Continue this research
Compare TNGX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TNGX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put TNGX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance vopimetostat clinical trials
Positive clinical data support vopimetostat, though the stock reaction does not negate the trial progress.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $22.53
The last 12 months of price, then the range of analyst 12-month targets from today’s $22.53.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Advance vopimetostat clinical trials
Positive trial results advance vopimetostat clinical trials.
Advances: Advance vopimetostat clinical trials
Increased price target reflects confidence in trial data.
Advances: Secure additional capital
Stock offering secures additional capital for operations.
Advances: Advance vopimetostat clinical trials
Combination data enhances prospects for vopimetostat.
Advances: Advance vopimetostat clinical trials
Surge in stock reflects strong trial data impact.
Advances: Advance vopimetostat clinical trials
Significant stock surge indicates positive trial results.
Threatens: Advance vopimetostat clinical trials
Shift in strategy could impact vopimetostat's progress.